Current estrogen-progestin and estrogen replacement therapy in elderly women: Association with carotid atherosclerosis

Annals of Epidemiology

Volumn 6, Issue 4, 1996, Pages 314-323

  Jonas, Helen A ^a   Kronmal, Richard A ^b   Psaty, Bruce M ^b   Manolio, Teri A ^c   Meilahn, Elaine N ^e   Tell, Grethe S ^d   Tracy, Russell P ^f   Robbins, John A ^g   Anton Culver, Hoda ^h  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF VERMONT   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; carotid arterial wall thickness; carotid stenosis; combined estrogen progestin replacement therapy; elderly women; estrogen replacement therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; ECHOGRAPHY; ELDERLY CARE; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE;

EID: 0030197508     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(96)00048-8     Document Type: Article

References (52)

1. 1. Arteriosclerosis 1981, Report of the Working Group on Arteriosclerosis of the NHLBI. Publication no. NIH 81-2034. Bethesda, MD: National Institutes of Health, June 1981.
2. 2. Gerstenblith G, Weisfeldt ML, Lakatta EG. Disorders of the heart. In: Andres R, Bierman E, Hazzard W, eds. Principles of Geriatric Medicine. New York: McGraw Hill; 1985:104-119.
3. 3. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
4. 4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
5. 5. Sullivan JM, Zwaag RV, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 1988;108:358-363.
6. 6. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinscki KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 1988;115:954-963.
7. 7. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries J O'N. Risk factors and non-contraceptive estrogen use in women with and without coronary disease. Am Heart J. 1989;117:1209-1214.
8. 8. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
9. 9. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
10. 10. Sullivan JM, Zwaag RV, Hughes JP, et al. Estrogen replacement therapy and coronary artery disease. Effect of survival in postmenopausal women. Arch Intern Med. 1990;150:2557-2562.
11. 11. Fahraeus L, Wallentin L. High densitylipoprotein subfractions during oral and cutaneous administration of 17β-estradiol to menopausal women. J Clin Endocrinol Metab. 1983;56:789-801.
12. 12. Jensen J, Nilas L, Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J Obstet Gynaecol. 1986;93:613-618.
13. 13. Krauss RM, Perlman JA, Ray R, Petitti D. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstet Gynecol. 198;158:1606-1611.
14. 14. Persson I, Adami H-O, Bergvist L, et al. Risk of endometrial cancer treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J. 1989;298:147-151.
15. 15. Voight LF, Weiss NS, Chu J, Daling JR, McKnight D, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet, 1991;338:274-277.
16. 16. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SE, Stillman RJ. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotem A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol. 1994;83:173-179.
17. 17. Lobo RA, Pickar JH, Wils RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 1994;84:987-995.
18. 18. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
19. 19. Falkeborn M, Persson I, Adami H-O, et al. The risk of acute myocardial infarction after estrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99:821-828.
20. 20. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in post-menopausal women. Arch Intern Med. 1994;154:1333-1339.
21. 21. Stampfer MJ, Grodstein F, Colditz GA, et al. Estrogen and estrogen/progestin and risk of cardiovascular disease: Prospective data from the Nurses' Health Study. Am J Epidemiol. 1995;141:S57.
22. 22. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol. 1991;1:263-279.
23. 23. Manolio TM, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation. 1993;88:2163-2171.
24. 24. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358-366.
25. 25. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
26. 26. Taylor HL, Jacobs DR, Schucker B, Knudsen J, Leon AS, Debacker G. A qestionnaire for the assessment of leisure time physical activities. J Chron Dis. 1978;31:741-755.
27. 27. Psaty BM, Lee M, Savage PJ, Rutan GH, Lyles M. Assessing the use of medications in the elderly: Methods and initial results in the Cardiovascular Health Study. J Clin Epidemiol. 1992;45:683-692.
28. 28. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992;23:1752-1760.
29. 29. O'Leary DH, Polak JF, Wolfson SK, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly: The Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
30. 30. Tell GS, Howard G, McKinney WM. Risk factors for site specific extracranial carotid artery plaque distribution as measured by B-mode ultrasound. J Clin Epidemiol. 1989;42:551-559.
31. 31. Harris RB, Laws A, Reddy VM, King A, Haskell WL. Are women using postmenopausal estrogens? A community survey. Am J Public Health. 1990;80:1266-1268.
32. 32. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
33. 33. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA. 1989;261: 2095-2100.
34. 34. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990;163:1438-1444.
35. 35. Tikkanen MJ, Kuusi T, Nikkila EA, Sipenen S. Post-menopausal hormone replacement therapy: Effects of progestogens on serum lipids and lipoproteins. A review. Maturitas. 1986;8:7-17.
36. 36. Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L. Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XIII. J Lab Clin Med. 1988;111:52-56.
37. 37. Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D for the ACAPS Investigators. Am J Epidemiol. 1995; 142:1011-1119.
38. 38. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
39. 39. Tribble DL, Kruass RM. HDL and coronary artery disease. Adv Intern Med. 1993;38:1-29.
40. 40. Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol. 1980;12:564-569.
41. 41. De Lignieres B. The case for a nonplasma lipoprotein etiology of reduced vascular risk in estrogen replacement therapy. Curr Opinion Obstet Gynecol. 1993;5:389-395.
42. 42. Wagner JC, St. Clair RW, Schwenke DC, Shively CA, Adams MR, Clarkson TB. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Arterioscler Thromb. 1992;12:717-726.
43. 43. Cheng LP, Kuwahara M, Jacobsson J, Foegh ML. Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta allografts. Transplantation. 1991;52:967-972.
44. 44. Makila U-M, Wahlberg L, Viinikka L, Ylikorkala O. Regulation of prostaglandin and thromboxane production by human umbilical vessels: The effect of estradiol and progesterone in a superfusion model. Prostaglandins Leukotrienes and Medicine. 1982;8:115-124.
45. 45. Collins P, Rosano GMC, Jiang C, Lindsay D, Sorrel PM, Poole-Wilson PA. Cardiovascular protection by estrogen - a calcium antagonist effect? Lancet. 1993;341:1264-1265.
46. 46. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
47. 47. Volterrani M, Rosano GMC, Collins P. Effect of estradiol-17β upon forearm blood flow in menopausal women. A double blind randomized study. Circulation. 1993;88(Part 2):I-376.
48. 48. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
49. 49. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90:786-791.
50. 50. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
51. 51. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet. 1991;338:839-842.
52. 52. Penotti M, Nencioni T, Gabrielli L, Farini M, Castiglioni E, Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. Am J Obstet Gynecol. 1993;169:1226-1232.